Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
Robert E ShapiroHelen M HochstetlerEllen B DennehyRashna KhannaErin Gautier DotyPaul H BergAmaal J StarlingPublished in: The journal of headache and pain (2019)
ClinicalTrials.gov NCT02439320 (SAMURAI), registered 18 March 2015 and ClinicalTrials.gov NCT02605174 (SPARTAN), registered 11 November 2015.
Keyphrases
- placebo controlled
- double blind
- cardiovascular risk factors
- phase iii
- clinical trial
- phase ii
- study protocol
- phase ii study
- cardiovascular disease
- liver failure
- metabolic syndrome
- respiratory failure
- drug induced
- type diabetes
- aortic dissection
- squamous cell carcinoma
- acute respiratory distress syndrome
- replacement therapy
- rectal cancer
- hepatitis b virus